Selegiline: a second look. Six years later: too risky in Parkinson's disease.

  • Published 2002 in Prescrire international


(1) The reference treatment for Parkinson's disease is levodopa plus a peripheral dopadecarboxylase inhibitor (benserazide or carbidopa). (2) In 1996, selegiline, a type B MAOI marketed in France since 1988, saw its indications extended to cover single-agent therapy of early-stage Parkinson's disease, and in combination with levodopa, before onset of… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.